TY - JOUR
T1 - Plasma levels of soluble receptor for advanced glycation end products are associated with endothelial function and predict cardiovascular events in nondiabetic patients
AU - Chiang, Kuang Hsing
AU - Huang, Po Hsun
AU - Huang, Shao Sung
AU - Wu, Tao Cheng
AU - Chen, Jaw Wen
AU - Lin, Shing Jong
PY - 2009/6
Y1 - 2009/6
N2 - We sought to test the hypothesis that decreased plasma soluble receptor for advanced glycation end products (sRAGE) levels were associated with endothelial dysfunction in nondiabetic patients. sRAGE, a C-truncated secretary isoform of the receptor protein, has been shown to neutralize vascular damage mediated by advanced glycation end products, and has been implicated in atherogenesis. However, the relation between plasma sRAGE level and endothelial function remains unclear. Plasma levels of sRAGE were examined in 180 nondiabetic participants with suspected coronary artery disease. Endothelial function was evaluated by endothelium-dependent flow-mediated vasodilation (FMD) of the brachial artery. The primary end point was the combined occurrence of major adverse cardiovascular events, including nonfatal myocardial infarction, revascularization with percutaneous coronary intervention or coronary artery bypass grafting, ischemic stroke, and cardiovascular death. there were 23 events (26%) in the lower sRAGE group (≤ median, 809 pg/ml) and 11 events (12%) in the higher sRAGE group (>809 pg/ml; P<0.05). By the Kaplan-Meier analysis, it was shown that enhanced plasma levels of sRAGE were associated with better major adverse cardiovascular event-free survival (P= 0.032). The results indicate that plasma sRAGE levels are positively associated with endothelial function and predict cardiovascular events in nondiabetic participants with suspected coronary artery disease, suggesting its pivotal role in atherothrombosis.
AB - We sought to test the hypothesis that decreased plasma soluble receptor for advanced glycation end products (sRAGE) levels were associated with endothelial dysfunction in nondiabetic patients. sRAGE, a C-truncated secretary isoform of the receptor protein, has been shown to neutralize vascular damage mediated by advanced glycation end products, and has been implicated in atherogenesis. However, the relation between plasma sRAGE level and endothelial function remains unclear. Plasma levels of sRAGE were examined in 180 nondiabetic participants with suspected coronary artery disease. Endothelial function was evaluated by endothelium-dependent flow-mediated vasodilation (FMD) of the brachial artery. The primary end point was the combined occurrence of major adverse cardiovascular events, including nonfatal myocardial infarction, revascularization with percutaneous coronary intervention or coronary artery bypass grafting, ischemic stroke, and cardiovascular death. there were 23 events (26%) in the lower sRAGE group (≤ median, 809 pg/ml) and 11 events (12%) in the higher sRAGE group (>809 pg/ml; P<0.05). By the Kaplan-Meier analysis, it was shown that enhanced plasma levels of sRAGE were associated with better major adverse cardiovascular event-free survival (P= 0.032). The results indicate that plasma sRAGE levels are positively associated with endothelial function and predict cardiovascular events in nondiabetic participants with suspected coronary artery disease, suggesting its pivotal role in atherothrombosis.
KW - Cardiovascular events
KW - Endothelial function
KW - Soluble receptor for advanced glycation end products
UR - http://www.scopus.com/inward/record.url?scp=67649668763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67649668763&partnerID=8YFLogxK
U2 - 10.1097/MCA.0b013e32832c459c
DO - 10.1097/MCA.0b013e32832c459c
M3 - Article
C2 - 19440065
AN - SCOPUS:67649668763
SN - 0954-6928
VL - 20
SP - 267
EP - 273
JO - Coronary Artery Disease
JF - Coronary Artery Disease
IS - 4
ER -